Molecular evidence for drug-induced compartmentalization of HIV-1 quasispecies in a patient with periodic changes to HAART

AIDS

Volumn 14, Issue 15, 2000, Pages 2265-2272

  Wang, Y M ^a   Dyer, W B ^a   Workman, C ^a   Wang, B ^a   Sullivan, J S ^a   Saksena, N K ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

Compartmentalization; HAART; HIV; Resistance mutations; Viral evolution

Indexed keywords

ANTIGEN P24; ANTIRETROVIRUS AGENT; DIDANOSINE; HYDROXYUREA; INDINAVIR; LAMIVUDINE; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ANALYTIC METHOD; ARTICLE; CASE REPORT; CELL COMPARTMENTALIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; MONONUCLEAR CELL; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROVIRUS; TISSUE DISTRIBUTION; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS ACTIVATION; VIRUS GENE; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COCULTURE TECHNIQUES; DRUG RESISTANCE, MICROBIAL; EVOLUTION, MOLECULAR; FOLLOW-UP STUDIES; GENES, ENV; GENES, POL; HIV INFECTIONS; HIV PROTEASE; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; LONGITUDINAL STUDIES; MALE; MUTATION; ZIDOVUDINE;

EID: 0033764544     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200010200-00007     Document Type: Article

References (16)

1. Recovery of the immune system with anti-retroviral therapy: The end of opportunism
2. Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: Survey of 787 sequences
3. Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type I isolates from patients with combination antiretroviral therapy failure
4. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development
5. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy
6. Comparison of human immunodeficiency virus type 1 (HIV-1) protease mutations in HIV-1 genomes detected in plasma and in peripheral blood mononuclear cells from patients receiving combination drug therapy
7. Evaluation of cell-free and cell-associated peripheral blood human immunodeficiency virus type I RNA response to antiretroviral therapy
8. Gene defects clustered at the C-terminus of the vpr gene of HIV-1 long-term non-progressing mother-child pair: In vivo evolution of vpr quasispecies in blood and plasma
9. Clustal W. Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice
10. Rapid, transient changes at the env locus of plasma HIV-1 population during the emergence of protease inhibitor resistance
11. Human immunodeficiency virus type I genetic evolution in patients with prolonged suppression of plasma viremia
12. HIV-1 viral background plays a major role in the development of resistance to protease inhibitors
13. Loss of viral fitness associated with multiple gag and gag-pol processing defects in HIV-1 variants selected for resistance to protease inhibitors in vivo
14. Evaluation of proviral copy number and plasma RIgA level as early indicators of progression in HIV-1 infection: Correlation with virological and immunological markers of disease
15. Quantification of human immunodeficiency virus type 1 tat mRNA as a marker for assessing the efficacy of antiretroviral therapy